Novidades Científicas

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) – Long Term Outcomes

14 Março 2018

Hospital Performance Based on 30-Day Risk Standardized Mortality and Long-Term Survival after Hearth Failure Hospitalization an Analysis of the GWTG-HF Registry

14 Março 2018

Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs – Real World Data Across Three Major World Regions With More Than 400.000 Patients: The CVD-REAL 2 Study

14 Março 2018

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

14 Março 2018

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

14 Março 2018

European Society of Cardiology: Cardiovascular Disease Statistics 2017

6 Dezembro 2017

European Cardiovascular Disease Statistics 2017

28 Setembro 2017

CETP inhibitor meets primary endpoint in CV outcome study

29 Junho 2017

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial

10 Abril 2017

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

10 Abril 2017

Página 2 de 4